在医疗领域的3D打印时partnered with Organovo研究生物打印的人体组织的生存能力，以测试新药物。现在，随着Johnson＆Johnson Innovation启动了一套新的合作伙伴关系，重点关注公司以外的研发和产品开发，Johnson＆Johnson宣布将与Carbon 3D合作生产定制的手术设备。
去年，Carbon 3D全世界都在谈论他们的超快速连续液体界面生产（CLIP）技术。随着新闻媒体将夹3D打印与“终结者中的那个场景”进行比较，Carbon 3D的技术承诺将无需透明印刷，这是由于其DLP样3D打印系统中的可渗透密封件。除了材料强度与注入成型竞争的外，夹技术能够在不到10分钟的时间内创建对象。他们的过程已经被FordandLegacy Effects, with Ford in particular deeming it to be more suitable for producing prototype parts. Given the disruptive potential of their technology, it’s no wonder that Johnson & Johnson chose to work with Carbon 3D over other players in the field.
As Johnson & Johnson Innovation and Janssen Pharmaceuticals, announce 21 partnerships across its Consumer, Medical Devices and Pharmaceuticals sectors, the company has picked Carbon 3D to develop custom surgical devices. Thepress releasedoes not go into deal about the partnership, but there are numerous examples of patient-specific, 3D printed surgical devices being created from CT or MRI scans and used to increase the predictability and efficiency of a surgery. Unlike other technologies that may 3D print these devices in a matter of hours, Carbon 3D will be able to produce them in a matter of minutes. To create such products, however, the company will likely need to implement a material approved by the FDA for surgical use.
Other partnerships and initiatives announced alongside the deal with Carbon 3D include treating infectious diseases like Chagas, developing new HIV medicines, and testing the viability of organoids for disease modeling, which pairs well with their previous study with Organovo. While, on the one hand, this demonstrates the increased use of Carbon 3D’s CLIP technology by huge corporations, it also provides evidence of Johnson & Johnson’s adoption of 3D printing for new medical applications, both of which have big implications for the future of medicine and 3D printing as a whole.
